Abrégé

The present invention solves the problem of providing novel and improved therapeutic compounds for preventing and/or treating cancer, such as ovarian cancer. The present invention provides compounds targeting TPM1 alternative splicing variants Tpm1.8 and/or Tpm1.9. The compounds or a pharmaceutical composition comprising at least one compound according to the present invention counteracts chemoresistance, such as chemoresistance to taxane- and/or platinum-based chemotherapeutic agents. Further, the present inventions includes a method for identifying compounds targeting Tpm1.8 and/or Tpm1.9 isoforms which have a therapeutic effect in inhibiting, suppressing, preventing and/or treating cancer.

Classes IPC  ?

• A61K 31/404 - Indoles, p. ex. pindolol
• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention solves the problem of providing novel and improved therapeutic agents for preventing and/or treating Hepatitis E virus (HEV) infections. The present invention provides guanosine nucleotide analogs or a pharmaceutical composition comprising said analogs for preventing and/or treating HEV infections. The guanosine nucleotide analogs or a pharmaceutical composition comprising guanosine nucleotide analogs for preventing and/or treating HEV infections are for example administered in combination with one or more additional antivirals, such as IFN-α and/or ribavirin. Further, the present invention also provides a method of preventing and/or treating a HEV infection in a subject, comprising the step of administering a therapeutically effective amount of the guanosine nucleotide analogs to said subject.

Classes IPC  ?

• A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention provides a method for determining whether a sample comprises inducible HIV-1, the method comprising performing a reverse transcription, loop-mediated isothermal amplification (RT-LAMP) reaction with said sample with a primer set specific for Tat/Rev multiply spliced (ms) HIV-1 RNA and determining whether the sample comprises an amplification product of the RT-LAMP reaction, wherein the binding sites for the F2 and F1 primer or for the B2c and B1c primer of said primer set span a region in said Tat/Rev ms HIV-1 RNA that overlaps with the splice site of the intron interrupting the Tat and Rev coding sequences.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The present invention relates to an alpha spectrometry scanner for measuring one or more characteristics of radiation particles received from a radioactive sample under test, which sample is comprised in a radiopharmaceutical, said scanner comprising: detector means comprising a pixelated detector comprising a two dimensional array of detector pixels sensitive to said radiation particles received from said sample; a readout circuit in electric communication with said detector means, arranged to readout each pixel of said array, and wherein said readout circuit is arranged to generate, based on said readout of each of said detector pixels, a charge pattern for each hit of a radiation particle on said detector means, said charge pattern comprising spatial data, temporal data and energy deposited for each detector pixel of said array; spectroscopic analyser means in electric communication with said readout circuit to receive each charge pattern generated by said readout circuit, wherein said spectroscopic analyser means are arranged with a selective algorithm to extract features from said charge pattern and to identify and quantify a corresponding alpha particle of said sample based on said extracted features; a collimator arranged for selecting radiation particles that are on a path from said radioactive sample under test, towards said detector means, wherein said collimator is positioned in front of said detector means, and is comprised of an alpha particle vacuum collimator or an alpha particle air-flush collimator, said vacuum collimator or air-flush collimator is arranged to restrict the passage of said radiation particles and select particles on the path towards the pixels of the array of the pixelated detector.

Classes IPC  ?

• G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
• G01T 1/24 - Mesure de l'intensité de radiation avec des détecteurs à semi-conducteurs
• G01T 1/36 - Mesure de la distribution spectrale des rayons X ou d'une radiation nucléaire

Abrégé

The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 15/1404 - Manipulation du flux, p. ex. focalisation hydrodynamique
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent

Abrégé

An aspect of the disclosure relates to an ultrasound imaging system comprising: an ultrasound imaging device comprising an ultrasound transducer configured to transmit and receive ultrasound signals; and an ultrasound receiver device that is separable from the ultrasound imaging device, the ultrasound receiver device comprising: one or more ultrasound receiver elements configured to receive ultrasound signals, in which the one or more ultrasound receiver elements and the one or more ultrasound transducers are configured to operate simultaneously; an external housing configured to separate the one or more ultrasound receiver elements from the ultrasound imaging device, in which the one or more ultrasound receiver elements are within the external housing.

Classes IPC  ?

• G01S 7/52 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
• G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores

Abrégé

This invention relates to the field of primary immunodeficiencies (PID), more specifically to means and method for the diagnosis of PID of the lymphoid system. Provided are unique reagent compositions for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against various specific combinations of markers. Also provided are kits comprising the reagent compositions, and methods using the same.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 15/01 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux spécialement adaptée aux cellules biologiques, p. ex. aux cellules sanguines
• G01N 15/10 - Recherche de particules individuelles
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

Abrégé

The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Methods are provided for treating an individual with cytotoxic T lymphocyte exhaustion by administering an effective dose of an annexin V agent. In some embodiments, the individual undergoing treatment is infected with HIV. The individual may be treated with highly active antiretroviral therapy (HAART).

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.

Classes IPC  ?

• A01K 67/0278 - Vertébrés knock-in, p. ex. vertébrés humanisés
• A01K 67/0276 - Vertébrés knock-out
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12P 21/00 - Préparation de peptides ou de protéines

Abrégé

According to one aspect, an interstitial hyperthermia device has an electrode structure to be coupled to an electric power source for providing an alternating electric field for heating up a patients tissue. The device is provided with a hollow source guide for conducting a radiation source capsule to be moved by a guidewire. The hollow source guide has an inner wall for guiding the source capsule and an outer wall to be contacted with the patients tissue. The outer wall is provided with the electrode structure arranged on a circumference of the outer wall of the hollow source guide and having a dielectric layer shielding the electrode structure from the patients tissue.

Classes IPC  ?

• A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

The invention relates to a group of Y-chromosomal short tandem repeat (Y-STR) markers comprising at least one rapidly mutating (RM) Y-STR marker selected from the group consisting of DYF1000, DYF1001, DYF1002, DYR88, DYS685, DYS688, DYS712, DYS1003, DYS1007, DYS1010 and DYS1012. The invention further relates to a set of amplification primers comprising primers for the amplification of at least one Y-STR marker according to the invention, to methods for amplifying an allele of at least one Y-STR marker, to a kit for identifying an allele of a Y-STR marker by amplification and electrophoretic detection or sequencing detection, and by sequencing of non-amplified DNA, and to the use of the group of Y-STR markers for typing male individuals.

Classes IPC  ?

• C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes

Abrégé

Provided herein are bispecific antibodies comprising a first antigen binding region and a second antigen binding region, wherein the first antigen binding region binds to CD117 and comprises a first heavy chain variable region and a first light chain variable region, and the second binding reigon binds to CD3 and comprises a second heavy chain variable region and a second light chain variable region. Also provided are compositions comprising the bispecific antibodies as well as uses of the bispecific antibodies and compositions.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C07K 16/46 - Immunoglobulines hybrides
• A61P 35/00 - Agents anticancéreux
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The present invention provides a pharmaceutical combination for use in treating cancer comprising an ITK inhibitor and an immune checkpoint inhibitor, wherein the ITK inhibitor is formulated for intermittent administration or for administration at a dose that partially inhibits ITK enzymatic activity in T cells. The present invention further provides a method of reversing T cell exhaustion resulting from persistent TCR stimulation comprising exposing an exhausted T cell to an ITK inhibitor, wherein said T cell may be a CD8+ T cell or a CAR T cell.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention provides an in vitro method for determining the physiological age of blood platelets in a test sample wherein said physiological age is expressed in days and/or hours. The method comprises providing a test sample of blood platelets, determining the level of expression of one or more of tubulin, VWF, SPARC, CD63 and PF4 in one or more of individual platelets within said test sample, and determining, based on the level of expression determined, the physiological age of the blood platelets in said test sample. Preferably, the method comprises the using a machine learning data processing model.

Classes IPC  ?

• C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p. ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
• G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang

Abrégé

The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding a metabolic protein or a part thereof or a sequence having at least 90% sequence identity to said metabolic protein or part thereof, a human insulin-like growth factor II (IGFII) gene sequence, and a nucleotide sequence encoding at least one peptide that facilitates cellular uptake or transcytosis which is inserted at a location between the nucleotides encoding amino acids 28 and 42 of mature IGFII of said IGFII gene sequence. The invention further relates to related viral particles, fusion proteins and uses thereof.

Classes IPC  ?

• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/86 - Vecteurs viraux
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)

Abrégé

The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention is directed to a scaffold and a compound for targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs). The scaffold comprises a (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold that is substituted on the 8th22 or O; R132523232223222222m22m22, wherein m is 1-4; and R2and R3 each independently represent H or F.

Classes IPC  ?

• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 411/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 498/18 - Systèmes pontés
• A61P 35/00 - Agents anticancéreux
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles

Abrégé

A catheter-based imaging apparatus comprises a catheter having a proximal end and a distal end. An optical emitter is configured to emit optical excitation signals from a distal portion of the catheter. One or more ultrasound transducers are configured for: (a) transmission of acoustic excitation signals from the distal portion of the catheter; and (b) detection of ultrasound response signals from an object of interest at or near to the distal portion of the catheter at frequencies which include a lower receive frequency at least as low as 10 MHz and a higher receive frequency at least as high as 35 MHz. The one or more ultrasound transducers are thereby configured to detect response signals comprising photoacoustic response signals from the object of interest at the lower receive frequency and high resolution imaging signals from the object of interest at the higher receive frequency.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• A61B 8/08 - Applications cliniques
• A61B 8/12 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores dans des cavités ou des conduits du corps, p. ex. en utilisant des cathéters
• B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
• G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation

Abrégé

The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.

Classes IPC  ?

• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• C12N 9/22 - Ribonucléases
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire

Abrégé

The invention is directed to a pharmaceutical compound, or a pharmaceutically acceptable salt thereof, for use in a medical treatment or diagnosis of tumors, in particular neuroendocrine tumors (NET). The compound is according to the formula Ch(M)–L–T, wherein Ch represents a radioisotope chelator; M represents the radioisotope; T represents a sstr2-agonist; L represents a linker comprising a moiety having a six-membered cyclic structure.

Classes IPC  ?

• A61K 51/08 - Peptides, p. ex. protéines
• A61K 103/00 - Métaux radioactifs
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles

Abrégé

The present invention provides an anti-cancer vaccine composition comprising a cancer neoantigen comprising a CTL epitope, the composition further comprising as adjuvants a combination of a CpG ohgonucleotide and a STING agonist.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides an antiviral vaccine composition, comprising a viral coat, matrix or core/capsid (glyco)protein as antigen, and an adjuvant combination of a CpG oligonucleotide and a STING agonist.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding an amino acid sequence having at least 90% sequence identity with amino acids 28-952 of human acid alpha glucosidase (GAA) and a human insulin-like growth factor II (IGFII) gene sequence located 5' of the nucleotide sequence encoding an amino acid sequence having at least 90% sequence identity with amino acids 28-952 of human GAA, to encoded fusion proteins, and uses thereof.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/867 - Vecteurs rétroviraux

Abrégé

A system (100) and method for measuring tissue (T). A chamber (20) is configured to hold a liquid medium (L). Two attachments structures with respective tissue engaging sections (12) are configured to hold the tissue (T) there between inside the chamber (20c) and submerged in the liquid medium (L). At least one of the attachments structures is formed by a cantilever (10). The cantilever (10) comprises a respective bending section (11) formed by an elongate strip with a flat surface (11f) fixated at one end of the cantilever (10) and configured to bend with an, opposite, free end of the cantilever (10) in a direction normal to the flat surface (11f). The respective tissue engaging section (12) is connected at the free end of the cantilever (10) to the respective bending section (11) and configured to hold a respective part of the tissue (T) at said free end.

Classes IPC  ?

• C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
• C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

A stent delivery system (100) comprises a balloon-inflatable stent (10) with a guide wire (31) for guiding the stent (10) into a target vessel (V1) for treating a stenosis (4) in the target vessel (V1) with the stent (10) to be delivered at a predetermined stent position (Xs). An anchor wire (32) is provided through an anchor port (52) for anchoring the stent (10) by entering into a lumen or second vessel (V2) branching from the target vessel (V1) at a branching position (Xb). The anchor port (42) is freely adjustable along a length (ΔX) of the guide wire (31) for adjusting the anchor position (Xa) relative to the stent position (Xs), or vice versa. An anchor positioning means (41) is connected to the anchor port (42) and configured to control said freely adjustable anchor position (Xa) relative to the stent position (Xs), e.g. by pushing and pulling on a hypotube.

Classes IPC  ?

• A61F 2/958 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes ballons gonflables pour insérer les stents ou les endoprothèses déployables couvertes
• A61M 25/00 - CathétersSondes creuses
• A61F 2/954 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes pour insérer les stents ou les endoprothèses déployables couvertes dans une bifurcation

Abrégé

The current invention pertains an inhibitor of an S100 protein, preferably an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of primary myelofibrosis. The invention further pertains to an diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of an S100 protein, preferably S100A8 or S100A9, in a biological sample.

Classes IPC  ?

• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The invention provides a follistatin in combination with a bisphosphonate for use in a method of counteracting a condition of bone loss and/or muscle loss in a subject.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p. ex. acide clodronique, acide pamidronique
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
• A61P 21/06 - Agents anabolisants

Abrégé

The present invention provides a method of spreading DNA fibers on a surface of a microscope slide for microscopic analysis, the method comprising the steps of (i) providing a cell or cellular compartment comprising DNA fibers to be analyzed; (ii) providing a microscope slide for microscopic analysis; (iii) providing a container holding an amount of a liquid lysis composition for lysing said cell or cellular compartment; (iv) adhering said cell or cellular compartment to the surface of said microscope slide; (v) transferring said slide with said cell or cellular compartment adhered thereto to said container thereby substantially submerging said slide in said lysis composition, wherein said slide is placed in said lysis composition at a predetermined angle with respect to the horizontal plane of between 45° and 90°, and wherein the adhered cell or cellular compartment is facing upward; and (vi) allowing lysis of said cell or cellular compartment adhered to said slide, and removing said lysis composition from said container at a controlled and constant rate of flow by use of a liquid pump to thereby facilitate spreading of the DNA fibers on the surface of said microscope slide.

Classes IPC  ?

• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]

Abrégé

The invention relates to a device (1) and a method for obtaining an indicator of the microcirculatory condition of a patient. the device (1) comprises at least one sensor (2) for measuring data indicative of an arterial blood oxygen level, at least one sensor (3) for measuring data indicative of a tissue oxygen level and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion on the basis of the tissue oxygen level and the arterial blood oxygen level.

Classes IPC  ?

• A61B 5/026 - Mesure du débit sanguin
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 5/0205 - Évaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p. ex. de l'état cardiaque et respiratoire

Abrégé

The invention relates to a device (1, 1′) and a method for obtaining an indicator of microcirculatory condition of a patient. The device (1, 1′) comprises at least one first sensor (13) for measuring data indicative of first carbon dioxide levels, in particular tissue carbon dioxide levels, at least one second sensor (12) for measuring data indicative of second carbon dioxide levels, in particular transcutaneously measured arterial blood carbon dioxide levels, and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion, preferably in septic patients, on the basis of the tissue carbon dioxide level and the transcutaneously measured arterial blood carbon dioxide level.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/1477 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques non invasifs
• A61B 5/1491 - Applicateurs chauffés
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

in vitroin vitroin vitro condition wherein said oligomerization-modulating compound is absent, wherein said oligomerization-modulating compound is selected from a protein interacting with said oligomeric protein or its protein subunits, a nucleoside phosphate or an hydrolysis-resistant analogue thereof, or a (de)stabilizing small molecule; b) arresting the oligomerization of said protein oligomer by addition of a cross-linking agent to thereby provide said protein oligomer in a stabilized quaternary conformation and specific oligomeric state; c) using the protein oligomer in said stabilized quaternary conformation and specific oligomeric state of step (b) as a conformation-specific antigen of said protein oligomer to immunize a non-human mammal, optionally in combination with an adjuvant, to thereby obtain antibodies against said conformation-specific antigen; d) selecting an antibody obtained in step (c) that binds to the said conformation-specific antigen but not to said protein subunits, to thereby obtain a conformation-specific antibody against said oligomeric protein in a specific oligomeric state.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The invention provides novel immunogenic peptides derived from the X protein and polymerase protein of hepatitis B virus (HBV). The peptides contain epitopes that are well-conserved across multiple HBV variants and are derived from regions of proteins that are essential for viral replication. Moreover, the novel HBV antigens bind multiple HLA types and epitopes that elicit IFNγ responses in PBMCs from HBV resolvers have been identified.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/29 - Virus de l'hépatite
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention provides a reporter system comprising (i) a gene expression construct for expression in a cell of a reporter gene, said reporter gene encoding a fusion protein comprising a transmembrane domain fused in-frame to a reporter domain, wherein said transmembrane domain upon insertion of the fusion protein into the cell membrane anchors the fusion protein in the cell membrane while expressing the reporter domain at the cell surface, and (ii) a reporter peptide labeled with a radiolabel, wherein said reporter domain comprises the large polypeptide subunit of a split luciferase, and wherein said reporter peptide comprises the small peptide subunit of said split luciferase, wherein both subunits associate by complementation to assemble into a luciferase complex.

Classes IPC  ?

• A61K 51/08 - Peptides, p. ex. protéines
• C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention provides a method for the combined taxonomic identification and determination of antimicrobial drug resistance of a microorganism, proteins of which are present in a sample, the method comprising subjecting a sample comprising proteins of a microorganism to an endoprotease to provide a mixture of peptides from said proteins, and analyzing the mixture of peptides by high-resolution mass spectrometry using a single high resolution mass spectrometry technique in two separate data acquisition modes, wherein said modes consist of DDA and PRM, and wherein said two separate data acquisition modes are performed subsequently or in parallel in a single mass spectrometric analysis run.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A method of manufacturing a microstructure comprises printing a positive mold structure, filling the positive mold structure with a second material to form an elastically deformable negative mold structure, filling the negative mold structure with a third material to form the microstructure, and releasing the microstructure from the negative mold structure. Advantageously, the negative mold structure can be stretched to facilitate the release of the microstructure. For example, the microstructure comprises a chamber with capped micropillars for the generation and/or analysis of muscle tissue.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse

Abrégé

The invention provides a BAF complex modulating compound for use as a coronavirus antiviral; wherein the BAF complex modulating compound is of Formula (I):

Classes IPC  ?

• C07D 273/02 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle, non prévus par les groupes comportant deux atomes d'azote et un seul atome d'oxygène
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• C07D 273/08 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle, non prévus par les groupes comportant deux atomes d'azote et plusieurs atomes d'oxygène
• C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques

Abrégé

The disclosure relates to methods and devices for monitoring the concentration of a substance, preferably oxygen, in a cell or tissue, e.g., in cells of the human skin. In particular, it provides a method for determining the concentration of a quencher, such as oxygen and/or the concentration of a probe, e.g., a heme precursor such as protoporphyrin IX (PpIX), wherein the probe is capable of exhibiting luminescence (delayed fluorescence (DF) or phosphorescence) and or transient triplet absorption, preferably, deDF, in a living cell. The method comprises steps of exciting the probe, measuring the lifetime of the luminescence exhibited by said probe, herein, in the presence of the quencher, the lifetime is shortened as compared to the lifetime in the absence of the quencher, and correlating said lifetime with said concentration. The disclosed method leads to more precise results than conventional methods, because of adaptations based on the understanding of the influence of the concentration of the probe and its excitation fluence rate (intensity) on the analysis. For example, the simultaneous time-resolved detection of the probe excimer and monomer DF allows estimation of the probe concentration and compensation of the probe self-quenching effect in the quencher concentration calculation, increasing the measurement precision. Taking into account second order triplet interactions also permits the interpretation of non-exponential decays and further improvement of the quencher and probe concentration estimation. Disclosed methods rely, e.g., on measurement at different emission wavelengths and application of an adaptive Stern-Volmer relationship, the decay central fitting method and/or a mixed orders approach. Said method can be applied, e.g., for bedside monitoring of patients. Also disclosed is the use of the PpIX precursor 5-aminolevulinic acid (5-ALA), or derivatives thereof, in this method, and a device suitable therefor.

Classes IPC  ?

• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• G01N 21/64 - FluorescencePhosphorescence

Abrégé

The invention relates to antibodies that recognize SARS-CoV-2 spike protein (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and potently neutralize a broad range of SARS-CoV-2 variants of concern. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 15/13 - Immunoglobulines

Abrégé

e.g.e.g. serodiagnostic assays for SARS2).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 15/13 - Immunoglobulines

Abrégé

A fiber optic needle probe (100) comprising a length of optical fiber (10) inside a hollow needle (20) for supporting the optical fiber along its length. A distal end (10e) of the optical fiber (10) is formed by a formed convex tip (10t) protruding beyond a distal end (20e) of the hollow needle (20). Preferably, the distal end of the optical fiber (10) is formed by a formed conical tip with a cone angle less than hundred degrees. The shape of the convex tip (10t) formed at the distal end (10e) of the optical fiber (10) is found particularly suitable for repeated insertion into a tissue with minimal tendency of tissue residue sticking to the tip.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/1459 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale invasifs, p. ex. introduits dans le corps par un cathéter
• G02B 6/00 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage

Abrégé

The present invention provides a method for quantifying a monoclonal (M-) protein in a sample of a subject, the method comprising the steps of:—subjecting a serum sample of a subject to serum protein electrophoresis (SPE) in a gel, preferably serum protein electrophoresis in an agarose gel, to separate serum proteins into different serum protein fractions, optionally followed by immunofixation electrophoresis (IFE) and further optionally involving immunostaining of the gel;—excising from said gel a gel part comprising, or suspected of comprising, a M-protein;—performing an enzymatic digestion of proteins present in said gel part in order to provide a peptide digest comprising at least one M-protein peptide;—subjecting said peptide digest comprising said at least one M-protein peptide to liquid chromatography-mass spectrometry (LC-MS) to determine a quantity of said at least one M-protein peptide, thereby quantifying said M-protein in said sample.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

In an aspect of the invention there is provided an insufflator apparatus for exposing structures within a cavity of the human body for a diagnostic and/or therapeutic endoscopic procedure, comprising: an insufflation gas supply valve, adapted to provide insufflation gas to a pressure regulator; the pressure regulator, adapted to supply insufflation gas into the cavity of the human body via an input mechanism attachable to the human body, a means for determining a pressure level in the body cavity; an insufflator vent mechanism adapted to release excess insufflation gas volume returning from the pressure regulator; an insufflator controller arranged to real-time adapt an insufflation rate of said insufflation gas via said gas supply valve and vent mechanism at a set average pressure level in the body cavity in accordance with the means for determining the pressure level in the body cavity; and wherein the pressure regulator has a limited volume for temporarily storing a gas returning from the body cavity to thereby avoid transient pressure deviations from the set average pressure level in the body cavity, e.g. due to coughing or mechanical ventilation and s allowing the gas to return to the body cavity to maintain the set average pressure.

Classes IPC  ?

• A61M 13/00 - Insufflateurs à fins thérapeutique ou de désinfection
• A61B 17/34 - TrocartsAiguilles à ponction

Abrégé

The present invention provides a method for typing a tumor micro-environment (TME) of a solid tumor as being of the immune phenotype T cell-inflamed, T cell-excluded or T cell-ignored, comprising the steps of: - providing a test sample of a solid tumor comprising a TME from a subject; - measuring in said test sample the gene expression level for: (i) at least one gene selected from group 1 consisting of IGHG1, NKG7, IL2RG, IL7R, CCL18, PVRIG, PLAC8, CCL5, SIRPG, CORO1A, LCK, TRBC1, GZMB, CXCL13, and WARS; and (ii) at least one gene selected from group 2 consisting of COL5A1, SPON1, CAMK2N1, FAP, SPOCK1, COL1A1, SCGB2A1, AKR1C2, CPE, SCGB2A2, TCN1, TPSAB1, and MMP2; and (iii) at least one gene selected from group 3 consisting of PERP, THBS2, ASPN, COL10A1, TUFT1, GREM1, CEACAM6, ENTPD3, IGFBP5, PBX1, CXADR, GPRC5A, SDC1 and CALML5; - comparing the measured test sample gene expression levels to a reference gene expression level, and - typing the TME of said solid tumor of said subject as being T cell-inflamed, T cell-excluded or T cell-ignored on the basis of the comparison of said measured gene expression level and said reference gene expression level.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (iPS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 5/074 - Cellules souches adultes
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

The present invention relates to a method to determine bisulfite conversion of unmethylated cytosine to uracil in genomic DNA, comprising the steps of providing a first set of amplification primers for amplifying bisulfite converted copies of a repetitive DNA element by qPCR and a second set of amplification primers for amplifying unconverted copies of said repetitive DNA element by qPCR, performing a multiplex qPCR with said first and second set of amplification primers to generate amplicons, and determining the bisulfite conversion efficiency by comparing the amounts of said first and second amplicon.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

In an implantable medical device, a method of communicating with a control device is provided. The method comprises receiving a first data message from the control device via a first physical communication channel, upon receiving the first message, activating a second physical communication channel different from the first physical communication channel and obtaining first authentication data of the control device, based on data provided in the first data message. The method further comprises receiving, via the second physical communication channel, a second message, verifying whether the second message originates from the control device, based on the obtained first authentication data and deactivating the second physical communication channel at the side of the implantable medical device if a result of the verifying is that the second message does not originate from the control device.

Classes IPC  ?

• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
• A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
• H04L 9/00 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité

Abrégé

According to one aspect, an interstitial hyperthermia device has an electrode structure to be coupled to an electric power source for providing an alternating electric field for heating up a patients tissue. The device is provided with a hollow source guide for conducting a radiation source capsule to be moved by a guidewire. The hollow source guide has an inner wall for guiding the source capsule and an outer wall to be contacted with the patients tissue. The outer wall is provided with the electrode structure arranged on a circumference of the outer wall of the hollow source guide and having a dielectric layer shielding the electrode structure from the patients tissue.

Classes IPC  ?

• A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

Methods are provided for treating an individual with cytotoxic T lymphocyte exhaustion by administering an effective dose of an annexin V agent. In some embodiments, the individual undergoing treatment is infected with HIV. The individual may be treated with highly active antiretroviral therapy (HAART).

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a method for typing a subject for the presence or absence of a secondary liver cancer, comprising the steps of—measuring in a sample comprising peptides from a subject a peptide level for (i) a peptide comprising the amino acid sequence of SEQ ID NO:4 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:4; and/or (ii) a peptide comprising the amino acid sequence of SEQ ID NO:1 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1; and—typing said subject for the presence or absence of said secondary liver cancer on the basis of the measured peptide level.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

Classes IPC  ?

• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif

Abrégé

The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains
• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present disclosure pertains to the field of personalized medicine and methods for treating bladder cancer. In some embodiments, the disclosure relates to the use of long non-coding RNA (lncRNA) and genomic signatures for the prognosis of individuals with bladder cancer. The present disclosure provides methods for subtyping bladder cancer. The present disclosure also provides methods and compositions for treating bladder cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level of methylation in said CpG island of a control subject, is indicative of said CpG island being hypermethylated.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The invention provides a method for producing an auristatin-loaded liposome, comprising the steps of: - providing a liposome that encapsulates a remote loading agent; - generating a concentration gradient of said remote loading agent across the membrane of said liposome; - mixing said liposome with an aqueous medium comprising an auristatin; - loading said auristatin into said liposome; wherein said loading is driven by said concentration gradient; and - optionally, purifying an auristatin-loaded liposome.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique

Abrégé

The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention relates to antibody conjugates comprising an antibody and a nanoparticle conjugated to the antibody, wherein the nanoparticle comprises a payload, such as a gene editing payload. In some embodiments, the antibody-conjugated nanoparticles provide a means for treating a disease. In some embodiments, the antibody-conjugated nanoparticles are used to correct genetic defects in specific cell populations.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61P 35/00 - Agents anticancéreux

Abrégé

Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.

Classes IPC  ?

• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/08 - Virus à ARN

Abrégé

Described herein is a composition and method of preventing COVED- 19 with lipid-peptide fusion antiviral therapy.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/08 - Virus à ARN
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes

Abrégé

During hyperthermia treatment of the head and neck area a conventional water bolus, used in such treatment for guiding electromagnetic waves and cooling the patient's skin, may collapse onto the patients face due to the weight and/or pressure of the water inside the water bolus. An insert may be provided inside the water bolus to remedy this, wherein the insert provides additional stiffness and thus resistance against the water's weight and pressure. The insert however should not be too resistant against the shape of the patient, and thus an insert is provided with a first stiffness in a first load direction and a second stiffness in a second load direction, wherein the first stiffness is not equal to the second stiffness.

Classes IPC  ?

• A61F 7/00 - Appareils de chauffage ou de refroidissement pour traitement médical ou thérapeutique du corps humain

Abrégé

According to one method, a sample with cells contains a phototagging agent. The sample is imaged to identify at least one target cell to be isolated. The identified target cell in the sample is selectively irradiated with photo-activating light for selectively activating the phototagging agent in the target cell to change its fluorescence response. The irradiated target cell is isolated from other cells in the sample based on a difference in its fluorescence response compared to non-activated phototagging agent in the other cells. Further aspects are directed to a corresponding microscope system and chemical compound for use as the phototagging agent.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C09B 11/24 - Phtaléines contenant des groupes amine
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/00 - Microscopes

Abrégé

The invention relates to a recombinant adenovirus nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter, to a recombinant adenovirus nucleic acid wherein the adenoviral nucleotide sequence is mutated in such a way that it is no longer capable of producing one or more of the coat proteins, to cellular vesicles filled with such adenoviral material, cells provided with such adenoviral material and to methods and use thereof.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 15/86 - Vecteurs viraux
• C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
• A61K 35/761 - Adénovirus

Abrégé

An insufflator for exposing structures within an internal cavity forming a confined volume within an animal or human body, the apparatus including: an input conduit for exchanging gas with the confined volume; a gas insufflator for insufflation of gas into the confined volume through the input conduit, wherein the gas insufflator is configured to deliver an insufflator pressure to the confined volume, wherein the gas insufflator is configured to (super)impose at least one pressure or flow oscillation to obtain a forced oscillating pressure or flow delivered to the confined volume, the forced oscillating pressure or flow having at least one component with a frequency and an amplitude; a monitoring unit for monitoring a response of the internal cavity to the forced oscillating pressure or flow for determining one or more physical properties of the internal cavity; and an adapter unit for adjusting the insufflation pressure based on the determined one or more physical properties of the internal cavity.

Classes IPC  ?

• A61M 13/00 - Insufflateurs à fins thérapeutique ou de désinfection

Abrégé

The current invention pertains an inhibitor of an S100 protein, preferably an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of an S100A8 orS100A9 protein, for the prevention ortreatment of primary myelofibrosis. The invention further pertains to an diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of an S100 protein, preferably S100A8 or S100A9, in a biological sample.

Classes IPC  ?

• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61P 35/00 - Agents anticancéreux
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons

Abrégé

A method for distinguishing cells in a sample (S). The sample is provided with photoaffinity tags (T). Each tag (T) comprises a photoreactive moiety (Th) configured to hind to a nearby cell upon irradiation by photoactivating light (La), and a molecular identification structure (Ti) connected to the photoreactive moiety, A target location (St) of the sample (S) is determined with a target cell (Ct) to be distinguished. The target location (St) is selectively irradiated with the photoactivating light (La) to cause a photoactivated tag (T) to bind with the target cell (Ct) in the target location (St). The target cell (Ct) is distinguished from other cells (C) in the sample (S) by identifying the molecular identification structure (Ti) of the tag (T") bound to the target cell (Ct).

Classes IPC  ?

• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• C09B 11/08 - Phtaléines
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux

Abrégé

The current invention pertains an inhibitor of an S100 protein, preferably an inhibitor of an S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of an S100A8 orS100A9 protein, for the prevention ortreatment of primary myelofibrosis. The invention further pertains to an diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of an S100 protein, preferably S100A8 or S100A9, in a biological sample.

Classes IPC  ?

• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61P 35/00 - Agents anticancéreux
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons

Abrégé

The invention relates to a device (1, 1') and a method for obtaining an indicator of microcirculatory condition of a patient. The device (1, 1') comprises at least one first sensor (13) for measuring data indicative of first carbon dioxide levels, in particular tissue carbon dioxide levels, at least one second sensor (12) for measuring data indicative of second carbon dioxide levels, in particular transcutaneously measured arterial blood carbon dioxide levels, and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion, preferably in septic patients, on the basis of the tissue carbon dioxide level and the transcutaneously measured arterial blood carbon dioxide level.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/1477 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques non invasifs
• A61B 5/1491 - Applicateurs chauffés

Abrégé

The invention relates to a device (1, 1') and a method for obtaining an indicator of microcirculatory condition of a patient. The device (1, 1') comprises at least one first sensor (13) for measuring data indicative of first carbon dioxide levels, in particular tissue carbon dioxide levels, at least one second sensor (12) for measuring data indicative of second carbon dioxide levels, in particular transcutaneously measured arterial blood carbon dioxide levels, and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion, preferably in septic patients, on the basis of the tissue carbon dioxide level and the transcutaneously measured arterial blood carbon dioxide level.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/1477 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques non invasifs
• A61B 5/1491 - Applicateurs chauffés
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The invention relates to a device (1) and a method for obtaining an indicator of the microcirculatory condition of a patient. The device (1) comprises at least one sensor (2) for measuring data indicative of an arterial blood oxygen level, at least one sensor (3) for measuring data indicative of a tissue oxygen level and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion on the basis of the tissue oxygen level and the arterial blood oxygen level.

Classes IPC  ?

• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 5/1486 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques en utilisant des électrodes enzymatiques, p. ex. avec oxydase immobilisée
• A61B 5/1491 - Applicateurs chauffés

Abrégé

The invention relates to a device (1) and a method for obtaining an indicator of the microcirculatory condition of a patient. The device (1) comprises at least one sensor (2) for measuring data indicative of an arterial blood oxygen level, at least one sensor (3) for measuring data indicative of a tissue oxygen level and a control unit (4) for determining a measure of microcirculation, in particular changes in tissue perfusion on the basis of the tissue oxygen level and the arterial blood oxygen level.

Classes IPC  ?

• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 5/1486 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques en utilisant des électrodes enzymatiques, p. ex. avec oxydase immobilisée
• A61B 5/1491 - Applicateurs chauffés
• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

A method of manufacturing a microstructure comprises printing a positive mold structure, filling the positive mold structure with a second material to form an elastically deformable negative mold structure, filling the negative mold structure with a third material to form the microstructure, and releasing the microstructure from the negative mold structure. Advantageously, the negative mold structure can be stretched to facilitate the release of the microstructure. For example, the microstructure comprises a chamber with capped micropillars for the generation and/or analysis of muscle tissue.

Classes IPC  ?

• B29C 39/00 - Moulage par coulée, c.-à-d. en introduisant la matière à mouler dans un moule ou entre des surfaces enveloppantes sans pression significative de moulageAppareils à cet effet
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/26 - Inoculateur ou échantillonneur

Abrégé

The disclosure relates to methods and devices for monitoring the concentration of a substance, preferably oxygen, in a cell or tissue, e.g., in cells of the human skin. In particular, it provides a method for determining the concentration of a quencher, such as oxygen and/or the concentration of a probe, e.g., a heme precursor such as protoporphyrin IX (PplX), wherein the probe is capable of exhibiting luminescence (delayed fluorescence (DF) or phosphorescence) and or transient triplet absorption, preferably, deDF, in a living cell. The method comprises steps of exciting the probe, measuring the lifetime of the luminescence exhibited by said probe, wherein, in the presence of the quencher, the lifetime is shortened as compared to the lifetime in the absence of the quencher, and correlating said lifetime with said concentration. The disclosed method leads to more precise results than conventional methods, because of adaptations based on the understanding of the influence of the concentration of the probe and its excitation fluence rate (intensity) on the analysis. For example, the simultaneous time-resolved detection of the probe excimer and monomer DF allows estimation of the probe concentration and compensation of the probe self-quenching effect in the quencher concentration calculation, increasing the measurement precision. Taking into account second order triplet interactions also permits the interpretation of non-exponential decays and further improvement of the quencher and probe concentration estimation. Disclosed methods rely, e.g., on measurement at different emission wavelengths and application of an adaptive Stern-Volmer relationship, the decay central fitting method and/or a mixed orders approach. Said method can be applied, e.g., for bedside monitoring of patients. Also disclosed is the use of the PplX precursor 5-aminolevulinic acid (5-ALA), or derivatives thereof, in this method, and a device suitable therefor.

Classes IPC  ?

• G01N 21/64 - FluorescencePhosphorescence
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

An MR excitation sequence comprises a repeated block (A) of excitation pulses. Each block (A) comprises a set of interleaved RE pulses with alternating small and large flip angle (α,γ) applied along different axes (x,y) to form a balanced sequence such as αχ,γγ,αγ,γχ. The sequence is simultaneously sensitive to various parameters such as PD, Tl, T2, B1 and BO keeping a high coherence and avoiding the formation of banding artifacts.

Classes IPC  ?

• G01R 33/44 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance magnétique nucléaire [RMN]
• G01R 33/50 - Systèmes d'imagerie RMN basés sur la détermination des temps de relaxation

Abrégé

The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline

Abrégé

The present invention provides inter alia a self-assembling nanoparticle that displays on the outer surface a receptor binding domain (RBD) of a coronavirus spike (S) protein. The present prevention also relates to vaccine formulations and methods for therapeutic and prophylactic interventions for coronaviral infection, more in particular SARS-CoV-2, the causal agent of COVID-19.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-specific subunit (e.g., ARID1A) to prevent nucleosomal positioning, relieving transcriptional repression of HIV-1. The subject methods can provide for reversal of latency of HIV-1 in cells in vitro or in vivo. Use of the macrolactam BAF complex modulating compounds represent a method of HIV latency reversal with a unique mechanism of action, which can be optionally combined with other Latency Reversal Agents to improve reservoir targeting. The subject methods can be utilized in conjunction with any convenient methods of treating HIV or HIV latency, including methods related to immune system activation, antiretroviral therapies and/or anti-HIV agents.

Classes IPC  ?

• A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV

Abrégé

A method for magnetic resonance imaging (MRI) comprises applying a consecutive series of MRI sequences to a target volume (V) according to experimental settings (TR, α, β). A discrete sequence of transient response signals (Sn, Sn+1, Sn+2) is measured and fitted to a fit function (F) that is continuously dependent on a sequence number (n) of the respective MRI sequence (Pn) and corresponding response signal (Sn). A shape of the fit function is determined according to an analytically modelled evolution by the experimental parameters (TR, α, β) as well as variable intrinsic parameters (r, λ3, φ, δ) to be fitted. For example, the model is based on an equivalent harmonic oscillator. The intrinsic parameters of the fit function can be related to the intrinsic properties (PD, T1, T2) of the spin systems and used for imaging the target volume (V). Various optimizations of contrast can be achieved by tuning the experimental settings according to the model.

Classes IPC  ?

• G01R 33/50 - Systèmes d'imagerie RMN basés sur la détermination des temps de relaxation
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• G01R 33/54 - Systèmes de traitement du signal, p. ex. utilisant des séquences d'impulsions
• G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
• G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar

Produits et services

Provision of training and education, conducting of courses; organization of congresses, seminars, information meetings (educational) and other educational events; organization of events for cultural, entertainment and sporting purposes in the context of charitable activities; publication of printed matter and other publications. Science and technology services as well as associated research- and design services; industrial analysis and research services; computer and software design and development; medical research services.

Abrégé

The present invention provides a reporter system comprising (i) a gene expression construct for expression in a cell of a reporter gene, said reporter gene encoding a fusion protein comprising a transmembrane domain fused in-frame to a reporter domain, wherein said transmembrane domain upon insertion of the fusion protein into the cell membrane anchors the fusion protein in the cell membrane while expressing the reporter domain at the cell surface, and (ii) a reporter peptide labeled with a radiolabel, wherein said reporter domain comprises the large polypeptide subunit of a split luciferase, and wherein said reporter peptide comprises the small peptide subunit of said split luciferase, wherein both subunits associate by complementation to assemble into a luciferase complex.

Classes IPC  ?

• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase
• A61B 6/03 - Tomographie informatisée
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo

Abrégé

The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

Classes IPC  ?

• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

A device for protecting a gastro-intestinal anastomosis, in particular a colorectal anastomosis or an esophageal anastomosis, is provided. The device comprises a support structure providing a passage for allowing passage of gastro-intestinal content such as faecal matter and/saliva from a first end to a second end of the support structure, a first expandable compartment, connected to the support structure and circumferentially surrounding the support structure at or near the first end, wherein an outer diameter of the first expandable compartment is larger than an outer diameter of the support structure the first expandable compartment is in an expanded state.

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/11 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour réaliser l'anastomoseBoutons pour anastomose
• A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires
• A61F 2/848 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents avec des moyens de fixation à la paroi du vaisseau, p. ex. des barbes

Abrégé

The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Classes IPC  ?

• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 15/1404 - Manipulation du flux, p. ex. focalisation hydrodynamique

Abrégé

The invention relates to a group of Y-chromosomal short tandem repeat (Y-STR) markers comprising at least one rapidly mutating (RM) Y-STR marker selected from the group consisting of DYF1000, DYF1001, DYF1002, DYR88, DYS685, DYS688, DYS712, DYS1003, DYS1007, DYS1010 and DYS1012. The invention further relates to a set of amplification primers comprising primers for the amplification of at least one Y-STR marker according to the invention, to methods for amplifying an allele of at least one Y-STR marker, to a kit for identifying an allele of a Y-STR marker by amplification and electrophoretic detection or sequencing detection, and by sequencing of non-amplified DNA, and to the use of the group of Y-STR markers for typing male individuals.

Classes IPC  ?

• C12Q 1/6858 - Amplification spécifique d’allèles

Abrégé

A surgical navigation system (100) comprises a first detection system (10) configured to detect a first marker (11). A headset (40) comprises goggles (30) and a second detection system (20) configured to detect a distinct, reference marker (21). The goggles (30) provide a display to show an augmented image (la) in a user's field of view (Vu). A controller (50) is configured to generate the augmented image (la) based at least on respective coordinates (P11,P21) of the markers (11,21), and a predetermined spatial relation (ΔΡ) between the coordinates (P11,P21).

Classes IPC  ?

• A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
• G02B 27/01 - Dispositifs d'affichage "tête haute"
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
• A61B 90/50 - Supports pour instruments chirurgicaux, p. ex. bras articulés

Abrégé

−5. Also provided are diagnostic kits and methods for detecting MRD.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/02 - Antigènes bactériens
• A61K 39/09 - Streptococcus

Abrégé

The present invention provides a method for quantifying a monoclonal (M-) protein in a sample of a subject, the method comprising the steps of: - subjecting a serum sample of a subject to serum protein electrophoresis (SPE) in a gel, preferably serum protein electrophoresis in an agarose gel, to separate serum proteins into different serum protein fractions, optionally followed by immunofixation electrophoresis (IFE) and further optionally involving immunostaining of the gel; - excising from said gel a gel part comprising, or suspected of comprising, a M-protein; - performing an enzymatic digestion of proteins present in said gel part in order to provide a peptide digest comprising at least one M-protein peptide; - subjecting said peptide digest comprising said at least one M-protein peptide to liquid chromatography-mass spectrometry (LC-MS) to determine a quantity of said at least one M-protein peptide, thereby quantifying said M-protein in said sample.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 27/447 - Systèmes utilisant l'électrophorèse

Abrégé

The invention provides novel immunogenic peptides derived from the X protein and polymerase protein of hepatitis B virus (HBV). The peptides contain epitopes that are well-conserved across multiple HBV variants and are derived from regions of proteins that are essential for viral replication. Moreover, the novel HBV antigens bind multiple HLA types and epitopes that elicit IFN? responses in PBMCs from HBV resolvers have been identified.

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• C07K 14/02 - Hepadnaviridae, p. ex. virus de l'hépatite B

Abrégé

γγ responses in PBMCs from HBV resolvers have been identified.

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• C07K 14/02 - Hepadnaviridae, p. ex. virus de l'hépatite B

Abrégé

In an aspect of the invention there is provided an insufflator apparatus for exposing structures within a cavity of the human body for a diagnostic and/or therapeutic endoscopic procedure, comprising: an insufflation gas supply valve, adapted to provide insufflation gas to a pressure regulator; the pressure regulator, adapted to supply insufflation gas into the cavity of the human body via an input mechanism attachable to the human body, a means for determining a pressure level in the body cavity; an insufflator vent mechanism adapted to release excess insufflation gas volume returning from the pressure regulator; an insufflator controller arranged to real-time adapt an insufflation rate of said insufflation gas via said gas supply valve and vent mechanism at a set average pressure level in the body cavity in accordance with the means tor determining the pressure level in the body cavity; and wherein the pressure regulator has a limited volume for temporarily storing a gas returning from the body cavity to thereby avoid transient pressure deviations from the set average pressure level in the body cavity, e,g. due to coughing or mechanical ventilation and allowing the gas to return to the body cavity to maintain the set average pressure.

Classes IPC  ?

• A61M 13/00 - Insufflateurs à fins thérapeutique ou de désinfection
• A61B 17/34 - TrocartsAiguilles à ponction

Abrégé

The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.

Classes IPC  ?

• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées

Abrégé

The present invention relates to a method to determine bisulfite conversion of unmethylated cytosine to uracil in genomic DNA, comprising the steps of providing a first set of amplification primers for amplifying bisulfite converted copies of a repetitive DNA element by qPCR and a second set of amplification primers for amplifying unconverted copies of said repetitive DNA element by qPCR, performing a multiplex qPCR with said first and second set of amplification primers to generate amplicons, and determining the bisulfite conversion efficiency by comparing the amounts of said first and second amplicon.

Classes IPC  ?

• C12Q 1/6858 - Amplification spécifique d’allèles

Abrégé

This invention relates to the field of primary immunodeficiencies (PID), more specifically to means and method for the diagnosis of PID of the lymphoid system. Provided are unique reagent compositions for the flow cytometric immunophenotyping of leukocytes comprising fluorochrome-conjugated antibodies directed against various specific combinations of markers. Also provided are kits comprising the reagent compositions, and methods using the same.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
• G01N 15/01 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux spécialement adaptée aux cellules biologiques, p. ex. aux cellules sanguines
• G01N 15/10 - Recherche de particules individuelles

Abrégé

The invention relates to a method for typing a subject for the presence or absence of a secondary liver cancer, comprising the steps of - measuring in a sample comprising peptides from a subject a peptide level for (i) a peptide comprising the amino acid sequence of SEQ ID NO:4 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:4; and/or (ii) a peptide comprising the amino acid sequence of SEQ ID NO:1 or a peptide comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1; and - typing said subject for the presence or absence of said secondary liver cancer on the basis of the measured peptide level.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A microfluidic device for holding three dimensional cell structures (2), with a top cover plate (3), a bottom cover plate (4), and an insert (5) having a membrane (6) provided in an aperture in the insert (5) and extending in a plane of the insert (5). In operation the insert (5) is positioned between the top cover plate (3) and bottom cover plate (4) to form two flow channels (3a; 4a) on either side of the insert (5). The membrane (6) is provided with a plurality of pores (6a) for holding three dimensional cell structures, with a pore size of at least 50pm. The microfluidic device (1) may be applied for a real-time imaging application.

Classes IPC  ?

• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse

Abrégé

The invention relates to methods for rapid in vitro-generation of viable, exhausted T cells, comprising culturing of T cells in a medium comprising at least IL-7 and/or IL-15, and repeated antigen stimulation of said T cells to rapidly generate exhausted T cells. The invention further relates to a method for treating said T cells to prevent, alleviate, or accelerate the generation of exhausted T cells. Further, this invention relates to a cell culture comprising viable, exhausted T cells.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Produits et services

Scientific services relating to the identification, selection and isolation of human tissues and cells; Scientific research; Technical research by means of microscopy systems; Design of optical and microoptical components; Optical research; laboratory services; Design and development of software for the acquisition and control of microscopy systems for research and medical imaging; technical adjustment of microscopy systems for research and medical imaging; Development of pharmaceutical preparations and medicines; Research in relation to medicines; Pharmaceutical research services. Medical services by means of identifying, selecting, isolating, removing and treating cells; Medical imaging.